• Our 3-dimensional,
    spherical nucleic acid (SNA™) architecture
    unlocks the potential of nucleic acid therapeutics
    in multiple organs.

  • Our lead programs
    address diseases from inflammatory
    disorders to oncology.

Exicure, formerly AuraSense Therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs.